Book contents
- Hematopoietic Cell TransplantsConcepts, Controversies, and Future Directions
- Hematopoietic Cell Transplants
- Copyright page
- Dedications
- Contents
- The Editors
- List of Contributors
- Preface
- Chapter 1 A Brief History of Hematopoietic Cell Transplantation
- Chapter 2 Current Use and Trends in Hematopoietic Cell Transplantation
- Chapter 3 Biology: Critical Components of Hematopoietic Cell Transplantation
- Section 1 Recipient Selection for Hematopoietic Cell Transplantation
- Section 2 Donor Selection for Allogeneic Hematopoietic Cell Transplants: A Moving Target
- Section 3 Collecting and Processing of the Graft
- Chapter 10 CD34+ Cell Mobilization in Autologous and Allogeneic Hematopoietic Cell Transplants
- Chapter 11 New Perspectives in Manufacturing Hematopoietic Cells
- Section 4 Early Post-Transplant Interval
- Section 5 Infections after Hematopoietic Cell Transplantation: Progress?
- Section 6 Late Complications of Hematopoietic Cell Transplantation
- Section 7 Other Complications of Hematopoietic Cell Transplants
- Section 8 Prevention, Detection, and Treatment of Relapse after Hematopoietic Cell Transplants
- Section 9 Selection of Conditioning Regimen and Challenges with Different Types of T-Cell Depletion Methods
- Section 10 Hematopoietic Cell Transplants for Acute Leukemia and Myelodysplastic Syndrome
- Section 11 Hematopoietic Cell Transplants for Myeloproliferative Neoplasms
- Section 12 Hematopoietic Cell Transplants for Lymphomas: Changing Indications
- Section 13 Plasma Cell Dyscrasias: Hematopoietic Cell Transplants
- Section 14 Autotransplants for Solid Neoplasms
- Section 15 Hematopoietic Cell Transplants for Non-Neoplastic Diseases
- Section 16 Novel Transplant Strategies
- Section 17 Novel Cell Therapies and Manipulations: Ready for Prime-Time?
- Index
- References
Chapter 11 - New Perspectives in Manufacturing Hematopoietic Cells
from Section 3 - Collecting and Processing of the Graft
Published online by Cambridge University Press: 24 May 2017
Edited by
Reinhold Munker and
Edited in association with
Book contents
- Hematopoietic Cell TransplantsConcepts, Controversies, and Future Directions
- Hematopoietic Cell Transplants
- Copyright page
- Dedications
- Contents
- The Editors
- List of Contributors
- Preface
- Chapter 1 A Brief History of Hematopoietic Cell Transplantation
- Chapter 2 Current Use and Trends in Hematopoietic Cell Transplantation
- Chapter 3 Biology: Critical Components of Hematopoietic Cell Transplantation
- Section 1 Recipient Selection for Hematopoietic Cell Transplantation
- Section 2 Donor Selection for Allogeneic Hematopoietic Cell Transplants: A Moving Target
- Section 3 Collecting and Processing of the Graft
- Chapter 10 CD34+ Cell Mobilization in Autologous and Allogeneic Hematopoietic Cell Transplants
- Chapter 11 New Perspectives in Manufacturing Hematopoietic Cells
- Section 4 Early Post-Transplant Interval
- Section 5 Infections after Hematopoietic Cell Transplantation: Progress?
- Section 6 Late Complications of Hematopoietic Cell Transplantation
- Section 7 Other Complications of Hematopoietic Cell Transplants
- Section 8 Prevention, Detection, and Treatment of Relapse after Hematopoietic Cell Transplants
- Section 9 Selection of Conditioning Regimen and Challenges with Different Types of T-Cell Depletion Methods
- Section 10 Hematopoietic Cell Transplants for Acute Leukemia and Myelodysplastic Syndrome
- Section 11 Hematopoietic Cell Transplants for Myeloproliferative Neoplasms
- Section 12 Hematopoietic Cell Transplants for Lymphomas: Changing Indications
- Section 13 Plasma Cell Dyscrasias: Hematopoietic Cell Transplants
- Section 14 Autotransplants for Solid Neoplasms
- Section 15 Hematopoietic Cell Transplants for Non-Neoplastic Diseases
- Section 16 Novel Transplant Strategies
- Section 17 Novel Cell Therapies and Manipulations: Ready for Prime-Time?
- Index
- References
- Type
- Chapter
- Information
- Hematopoietic Cell TransplantsConcepts, Controversies and Future Directions, pp. 97 - 103Publisher: Cambridge University PressPrint publication year: 2000
References
Halme, DG, Kessler, DA. FDA regulation of stem cell based therapies. N Engl J Med. 2006;355(16):1730–5.CrossRefGoogle ScholarPubMed
The Code of Federal Regulations. Human cells, tissues and cellular and tissue-based products. 2014; Part 1271.Google Scholar
Eapen, M, O’Donnell, P, Brunstein, CG, Wu, J, Barowski, K, Mendizibal, A et al. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014;20(10):1485–92.CrossRefGoogle ScholarPubMed
Mielke, S, McIver, ZA, Shenoy, , Fellowes, V, Khuu, H, Stroncek, DF et al. Selectively T cell depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(12): 1855–61.CrossRefGoogle ScholarPubMed
Berz, D, McCormack, EM, Winer, ES, Colvin, GA, Quesenberry, PJ. Cryopreservation of hematopoietic stem cells. Am J Hematol. 2007;82(6): 463–72.CrossRefGoogle ScholarPubMed
Melillo, L, Cascavilla, N, Lerma, E, Corsetti, MT, Carella, AM. The significance of minimal residual disease in stem cell grafts and the role of purging: is it better to purge in vivo or in vitro? Acta Haematol 2005;114(4): 206–13.CrossRefGoogle ScholarPubMed
Sidney, LE, Branch, MJ, Dunphy, SE, Dua, HS, Hopkinson, A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32(6):1380–9.CrossRefGoogle ScholarPubMed
Basel, MT, Shrestha, TB, Bossmann, SH, Troyer, DL. Cells as delivery vehicles for cancer therapeutics. Ther Deliv. 2014;5(5):555–67.CrossRefGoogle ScholarPubMed
Lapteva, N, Vera, JF. Optimization manufacture of virus and tumor-specific T cells. Stem Cells Int. 2011;2011:434392. doi: 10.4061/2011/434392. Epub 2011 Sep 11.CrossRefGoogle ScholarPubMed
Gulen, D, Abe, F, Maas, S, Reed, E, Cowan, K, Pirruccello, S et al. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol. 2008;8(13–14):1728–36.CrossRefGoogle ScholarPubMed
Donia, M, Larsen, SM, Met, O, Svane, IM. Simplified protocol for clinical grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy. 2014;16(8):1117–20.CrossRefGoogle ScholarPubMed
Hanley, PJ, Mei, Z, Durett, AG, de Graca Cabreira-Harrison, M, Klis, M, Li, W et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum cell expansion system. Cytotherapy. 2014;16(8):1048–58.CrossRefGoogle ScholarPubMed
Tapia, F, Vogel, T, Genzel, Y, Behrendt, I, Hirschel, M, Gangemi, JD et al. Production of high-titer influenza A virus with adherent and suspension MDCK cells cultured in a single use hollow fiber bioreactor. Vaccine. 2014;32(8):1003–11.CrossRefGoogle Scholar
Canovas, D, Bird, N. Human AB serum as an alternative to fetal bovine serum for endothelial and cancer cell culture. ALTEX 2012;29(4):426–8.CrossRefGoogle ScholarPubMed
Read, E. Ancillary materials for cell and tissue-based products. US Pharmacopeia. Available from: http://c.ymcdn.com/sites/www.celltherapysociety.org/resource/resmgr/uploads/files/Cell Therapy Liaison Meetings/November 2011/2. CTLM_Read_29MOV2011.pdfGoogle Scholar
Winter, JM, Jacobson, P, Bullough, B, Christensen, AP, Boyer, M, Reems, JA. Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. Cytotherapy. 2014;16(7):965–75.CrossRefGoogle ScholarPubMed
Miller, JS, Rooney, CM, Curtsinger, J, McElmurry, R, McCullar, V, Verneris, MR et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014;20(8):1252–7. doi: 10.1016/j.bbmt.2014.05.004. Epub 2014 May 9.CrossRefGoogle ScholarPubMed
Lapteva, N, Szmania, SM, van Rhee, F, Rooney, CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncol. 2014:19(1–2):121–32.Google ScholarPubMed
Shu, Z, Heimfeld, S, Gao, D. Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant. 2014;49(4):469–76.CrossRefGoogle ScholarPubMed
Kozma, N, Speletz, H, Reiter, U, Lanzer, G, Wagner, T. Impact of 13.56-MHz radiofrequency identification systems on the quality of stored red blood cells. Transfusion. 2011;51(11):2384–90.CrossRefGoogle Scholar
Bielanski, A. Non-transmission of bacterial and viral microbes to embryos and semen stored in vapour phase of liquid nitrogen dry shippers. Cryobiology. 2005;50(2):206–10.CrossRefGoogle ScholarPubMed
Veronesi, E, Murgia, A, Caselli, A, Grisendi, G, Picinno, MS, Rasini, V et al. Transportation conditions for prompt use of ex vivo expanded and freshly harvested clinical-grade bone marrow mesenchymal stromal/stem cells for bone regeneration. Tissue Eng Part C Methods. 2014;20(3):239–51.CrossRefGoogle ScholarPubMed
Klingemann, H, Grodman, C, Cutler, E, Duque, M, Kadidlo, D, Klein, AK et al. Autologous stem cells transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusion. Transfusion. 2013;53(2):412–8.CrossRefGoogle Scholar
Eggenhofer, E, Popp, FC, Mendicino, M, Silber, P, Van’t Hof, W, Renner, P et al. Heart grafts tolerized through third-party multipotent cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med. 2013;2(8):595–606.CrossRefGoogle ScholarPubMed
Leen, AM, Bollard, CM, Mendizabal, AM, Shpall, EJ, Szabolics, P, Antin, JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23.CrossRefGoogle ScholarPubMed